Prometheus Biosciences, Inc.
Optimized anti-TL1A antibodies
Last updated:
Abstract:
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Status:
Grant
Type:
Utility
Filling date:
25 Nov 2019
Issue date:
23 Jun 2020